Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- Wall St futures mixed as tech wobbles again, Tesla gains
- Oil heads for weekly gain with focus on Middle East supply
- U.S. producer prices rise by 1.3% month-on-month in September
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts TVRD Hot Sheet
Join SI Premium – FREE
Tvardi Therapeutics (NASDAQ: TVRD) reported Q2 EPS of ($0.69), $0.01 better than the analyst estimate of ($0.70).
For earnings history and earnings-related data on Tvardi Therapeutics (TVRD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rosenblatt cautious on Netflix (NFLX), sees studios and NFLX not wanting to discuss 'genAI can radically reduce content cost structures'
- Lake Street Downgrades MDxHealth SA (MDXH) to Hold
- ZentoAI signs MOU to acquire China-based digital tech firm
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
